Molecular imaging of tumor invasion and metastases: The role of MRI

NMR in Biomedicine

Volumn 24, Issue 6, 2011, Pages 561-568

  Mccann, Thomas E ^a   Kosaka, Nobuyuki ^a   Turkbey, Baris ^a   Mitsunaga, Makoto ^a   Choyke, Peter L ^a   Kobayashi, Hisataka ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Invasion; Metastasis; Molecular imaging; MRI; Optical imaging; PET

Indexed keywords

CANCER; INVASION; METASTASIS; MOLECULAR IMAGING; OPTICAL IMAGING;

DENDRIMERS; ENZYME INHIBITION; IRON OXIDES; OPTICAL IMAGE STORAGE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; POSITRONS; PROBES; TUMORS;

MAGNETIC RESONANCE IMAGING;

2 [4 (6 FLUOROHEX 1 YNYL)BENZENESULFONYLAMINO] 3 METHYLBUTYRIC ACID F 18; CATHEPSIN; DENDRIMER; FERUMOXTRAN 10; FLUORODEOXYGLUCOSE; GADOLINIUM PENTETATE MEGLUMINE; GADOXETIC ACID; IRON OXIDE; MATRIX METALLOPROTEINASE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PENTETATE INDIUM IN 111; POLYAMIDOAMINE; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

BONE METASTASIS; CANCER INVASION; CANCER SCREENING; COLON CANCER; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SYNTHESIS; DRUG UPTAKE; EARLY CANCER; EARLY DIAGNOSIS; EXTRACELLULAR MATRIX; FLUORESCENCE IMAGING; HUMAN; IN VIVO STUDY; IONIZING RADIATION; KAPOSI SARCOMA; LIVER METASTASIS; LIVER PARENCHYMA; LYMPH NODE METASTASIS; METASTASIS; MOLECULAR IMAGING; MOLECULAR PROBE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; RETICULOENDOTHELIAL SYSTEM; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; WHOLE BODY MRI;

ANIMALS; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; MOLECULAR PROBES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS;

EID: 79960818838     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1590     Document Type: Review

References (52)

1. Sporn MB.The war on cancer.Lancet, 1996;347:1377-1381.
2. Weissleder R, Mahmood U.Molecular imaging.Radiology, 2001;219(2):316-333.
3. Avraamides CJ, Garmy-Susini B, Varner JA.Integrins in angiogenesis and lymphangiogenesis.Nat. Rev. Cancer, 2008;8:604-617.
4. Deryugina EI, Quigley JP.Matrix metalloproteinases and tumor metastasis.Cancer Met. Rev. 2006;25:9-34.
5. Mohamed MM, Sloane BF.Cysteine cathepsins: multifunctional enzymes in cancer.Nat. Rev. Cancer, 2006;6:764-775.
6. Josephs D, Spicer J, O'Doherty M.Molecular imaging in clinical trials.Target Oncol. 2009;4(3):151-168.
7. 111In-DTPA-N-TIMP-2: a radiopharmaceutical for imaging matrix metalloproteinase expression.Bioconjug. Chem. 2001;12(6):964-971.
8. Oltenfreiter R, Staelens L, Lejeune A, Dumont F, Frankenne F, Foidart JM, Slegers G.New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents.Nucl. Med. Biol. 2004;31(4):459-468.
9. Kopka K, Breyholz HJ, Wagner S, Law MP, Riemann B, Schroer S, Trub M, Guilbert B, Levkau B, Schober O, Schafers M.Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo.Nucl. Med. Biol. 2004;31(2):257-267.
10. Breyholz HJ, Wagner S, Faust A, Riemann B, Holtke C, Hermann S, Schober O, Schafers M, Kopka K.Radiofluorinated pyrimidine-2, 4, 6-triones as molecular probes for noninvasive MMP-targeted imaging.ChemMedChem. 2010;5(5):777-789.
11. 18F-labeled matrix metalloproteinase-2 inhibitor.Nucl. Med. Biol. 2003;30:119-125.
12. 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection.Eur. J. Nucl. Med. 2001;28(6):756-761.
13. Jiang T.Tumor imaging by means of proteolytic activation of cell-penetrating peptides.Proc. Natl. Acad. Sci. 2004;101:17, 867-17, 872.
14. Olson ES, Aguilera TA, Jiang T, Ellies LG, Nguyen QT, Wong EH, Gross LA, Tsien RY.In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer.Integr Biol (Camb), 2009;1(5-6):382-393.
15. Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY.Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides.Integr Biol (Camb), 2009;1(5-6):371-381.
16. McIntyre JO, Scherer RL, Matrisian LM.Near-infrared optical proteolytic beacons for in vivo imaging of matrix metalloproteinase activity.Methods Mol. Biol. 2010;622:279-304.
17. McIntyre JO, Matrisian LM.Optical proteolytic beacons for in vivo detection of matrix metalloproteinase activity.Methods Mol. Biol. 2009;539:155-174.
18. Weissleder R, Tung C-H, Mahmood U, Bogdanov A.In vivo imaging of tumors with protease-activated near-infrared fluorescent probes.Nat Biotechnol. 1999;17:375-378.
19. Tung C-H, Mahmood U, Bredow S, Weissleder R.In vivo imaging of proteolytic enzyme activity using a novel molecular reporter.Cancer Res. 2000;60:4953-4958.
20. Schellenberger E, Rudloff F, Warmuth C, Taupitz M, Hamm B, Schnorr J.Protease-specific nanosensors for magnetic resonance imaging.Bioconjug. Chem. 2008;19(12):2440-2445.
21. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L.Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging.Radiology, 1990;175:489-493.
22. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ.Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging.Radiology, 1990;175:494-498.
23. Hu FQ, Wei L, Zhou Z, Ran YL, Li Z, Gao MY.Preparation of biocompatible magnetite nanocrystals for in vivo magnetic resonance detection of cancer.Adv. Mater. 2006;18:2553-2556.
24. Vogl TJ, Hammerstingl R, Schwarz W, Kümmel S, Müller PK, Balzer T, Lauten MJ, Balzer JO, Mack MG, Schimpfky C, Schrem H, Bechstein WO, Neuhaus P, Felix R.Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.Invest. Radiol. 1996;31:696-708.
25. Petersein J, Saini S, Weissleder R.Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.Magn. Reson. Imag. Clin. North Am. 1996;4:53-60.
26. Weissleder R, Hahn PF, Stark DD, Elizondo G, Saini S, Todd LE, Wittenberg J, Ferrucci JT.Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging.Radiology, 1988;169:399-403.
27. Anzai Y, Blackwell KE, Hirschowitz SL, Rogers JW, Sato Y, Yuh WT, Runge VM, Morris MR, McLachlan SJ, Lufkin RB.Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer.Radiology, 1994;192:709-715.
28. Anzai Y, McLachlan S, Morris M, Saxton R, Lufkin RB.Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck.Am. J. Neuroradiol. 1994;15:87-94.
29. Svenson S, Tomalia DA.Dendrimers in biomedical applications - reflections on the field.Adv. Drug Deliv. Rev. 2005;57:2106-2129.
30. Tomalia DA, Reyna LA, Svenson S.Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging.Biochem. Soc. Trans. 2007;35:61-67.
31. Kobayashi H, Brechbiel MW.Dendrimer-based macromolecular MRI contrast agents: characteristics and application.Mol. Imag. 2003;2:1-10.
32. Cabanas RM.An approach for the treatment of penile carcinoma.Cancer, 1977;39:456-466.
33. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S, Beitsch P.The sentinel node in breast cancer - a multicenter validation study.N. Engl. J. Med. 1998;339:941-946.
34. Anzai Y.Superparamagnetic iron oxide nanoparticles: nodal metastases and beyond.Top. Magn. Reson. Imaging, 2004;15:103-111.
35. Guimaraes A, Tabatabei S, Dahl D, McDougal W, Weissleder R, Harisinghani M.Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer.Urology, 2008;71:708-712.
36. Harisinghani MG, Saksena M, Ross RW, Tabatabaei S, Dahl D, McDougal S, Weissleder R.A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation.Urology, 2005;66:1066-1071.
37. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R.Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.N. Engl. J. Med. 2003;348:2491-2499.
38. Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Tagaya Y, Brechbiel MW.Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent.Cancer Res. 2003;63:271-276.
39. Kobayashi H, Kawamoto S, Sakai Y, Choyke PL, Star RA, Brechbiel MW, Sato N, Tagaya Y, Morris JC, Waldmann TA.Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent.J. Natl. Cancer Inst. 2004;96:703-708.
40. Kobayashi H, Kawamoto S, Brechbiel MW, Bernardo M, Sato N, Waldmann TA, Tagaya Y, Choyke PL.Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticle.Neoplasia (New York), 2005;7:984-991.
41. Reimer P, Jahnke N, Fiebich M, Schima W, Deckers F, Marx C, Holzknecht N, Saini S.Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis.Radiology, 2000;217:152-158.
42. Kobayashi H, Kawamoto S, Saga T, Sato N, Hiraga A, Ishimori T, Akita Y, Mamede MH, Konishi J, Togashi K, Brechbiel MW.Novel liver macromolecular MR contrast agent with a polypropylenimine diaminobutyl dendrimer core: comparison to the vascular MR contrast agent with the polyamidoamine dendrimer core.Magn. Reson. Med. 2001;46:795-802.
43. Vogl TJ, Kümmel S, Hammerstingl R, Schellenbeck M, Schumacher G, Balzer T, Schwarz W, Müller PK, Bechstein WO, Mack MG, Söllner O, Felix R.Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.Radiology, 1996;200:59-67.
44. Hosseinzadeh K, Schwarz SD.Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue.J. Magn. Reson. Imaging, 2004;20:654-661.
45. Guo Y, Cai YQ, Cai ZL, Gao YG, An NY, Ma L, Mahankali S, Gao JH.Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging.J. Magn. Reson. Imaging, 2002;16:172-178.
46. Schmidt GP, Baur-Melnyk A, Herzog P, Schmid R, Tiling R, Schmidt M, Reiser MF, Schoenberg SO.High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system.Invest. Radiol. 2005;40:743-753.
47. Schlemmer H-P, Schäfer J, Pfannenberg C, Radny P, Korchidi S, Müller-Horvat C, Nägele T, Tomaschko K, Fenchel M, Claussen CD.Fast whole-body assessment of metastatic disease using a novel magnetic resonance imaging system: initial experiences.Invest. Radiol. 2005;40:64-71.
48. Krishnamurthy GT, Tubis M, Hiss J, Blahd WH.Distribution pattern of metastatic bone disease. A need for total body skeletal image.J. Am. Med. Assoc. 1977;237:2504-2506.
49. Nakamoto Y, Osman M, Wahl RL.Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG.Clin. Nucl. Med. 2003;28:302-307.
50. Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Reiser MF, Baur-Melnyk A.Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT.Eur. Radiol. 2007;17:939-949.
51. Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA.Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer.Eur. Radiol. 2004;14:99-105.
52. Steinborn MM, Heuck AF, Tiling R, Bruegel M, Gauger L, Reiser MF.Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system.J. Comput. Assist. Tomogr. 1999;23:123-129.